Replimune Cuts Its Losses and Starts Writing Scripts: Inside the Quarter That Lifted the Stock 18%
Published on 10/29/2026 at 00:30 | Editorial boerse-global.de
Replimune's fiscal second-quarter report landed with two distinct storylines that investors chose to read together: a lighter cost base and the first tangible signs that TUDRIQEV is reaching patients. Shares climbed 18% on the day, and the reasons go well beyond the headline loss figure.
A Smaller Burn, With a Caveat
The company trimmed its net loss to $57.1 million for the quarter ended September 30, down from $83.1 million a year earlier. The improvement came from both sides of the ledger. Research and development spending fell to $34.4 million from $57.9 million, while selling, general and administrative costs eased to $21.9 million from $26.4 million.
That is a meaningful reduction in the quarterly cash burn. It is not, however, evidence of a self-sustaining commercial operation. The first shipments of TUDRIQEV fell outside the reporting period, and Replimune still offers no revenue guidance, leaving the transition from spending to earning impossible to quantify from the outside.
The Balance Sheet Behind the Optimism
Cash and cash equivalents stood at $307.8 million as of September 30. Management reckons that sum funds operations for more than twelve months from the publication of the financial statements, a runway that includes the TUDRIQEV commercialization effort.
Should investors sell immediately? Or is it worth buying Replimune?
That cushion was reinforced by an August equity offering that raised $141 million net. Against it, the operating cash outflow for the six months to September 30 came to $123.4 million. The runway estimate describes how long the existing funds last — not when the company reaches profitability — and it must absorb both the sales build-out and the ongoing clinical programs.
Prescriptions Begin to Accumulate
Roughly a month into the U.S. commercial launch, more than 15 institutions have written prescriptions for TUDRIQEV, according to Replimune. The company has also made contact with over 70% of the 200 accounts it initially prioritized.
Reaching out and writing a script are different milestones, and the distinction matters when weighing the update. The first measures sales effort; the second moves closer to actual use. Replimune adds that payer reimbursement policies cover TUDRIQEV in line with its approval, and that the therapy carries a Category 2A recommendation in the NCCN guidelines.
Replimune at a turning point? This analysis reveals what investors need to know now.
A Conditional Approval and Its Confirmatory Test
The regulatory backdrop is the FDA's accelerated approval, granted August 6, for TUDRIQEV combined with nivolumab in certain adults with advanced, unresectable cutaneous melanoma. That clearance can depend on confirming clinical benefit, which keeps the confirmatory IGNYTE-3 trial — now enrolling — squarely in the risk column. RP2-REVEAL is also actively recruiting.
Those studies run in parallel with commercialization, and they compete for the same cash. The quarter's results make a solid case for cost discipline and a narrower loss; durable economic progress will require product sales that can eventually carry the load. Until those numbers arrive, the clinical confirmation stands as a separate factor in how the company is valued — one that no amount of expense control can settle.
Ad
Replimune Stock: New Analysis - 29 October
Fresh Replimune information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
